Efficacy and tolerability of treatment with pegvisomant in acromegaly: an overview of literature

Bibliography

• Ben-Shlomo A, Melmed S. Acromegaly. Endocrinol Metab Clin North Am 2008;37(1):101-22
   PubMed Web of Science ®Google Scholar
• Melmed S. Medical progress: acromegaly. N Engl J Med 2006;355(24):2558-73
   PubMed Web of Science ®Google Scholar
• Rosario PW, Calsolari MR. Screening for acromegaly by application of a single questionnaire evaluating the enlargement of extremities in adult patients seen at primary health care units. Pituitary 2012;15(2):179-83
   PubMed Web of Science ®Google Scholar
• Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. Clin Endocrinol Metab 2006;91:4769-75
   Google Scholar
• Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest 2009;119(11):3189-202
   PubMed Web of Science ®Google Scholar
• Colao A, Lombardi G. Growth-hormone and prolactin excess. Lancet 1998;352(9138):1455-61
   Google Scholar
• Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009;94(5):1509-17
   PubMed Web of Science ®Google Scholar
• Giustina A, Barkan A, Chanson P, et al. Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. J Endocrinol Invest 2008;31(9):820-38
   PubMed Web of Science ®Google Scholar
• Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 2008;159(2):89-95
   PubMed Web of Science ®Google Scholar
• Giustina A, Chanson P, Bronstein MD, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010;95(7):3141-8
   PubMed Web of Science ®Google Scholar
• Colao A, Martino E, Cappabianca P, et al. First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group. J Endocrinol Invest 2006;29(11):1017-20
   Google Scholar
• Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical “cure”. Eur J Endocrinol 2005;152(3):379-87
   PubMed Web of Science ®Google Scholar
• Giustina A, Chanson P, Kleinberg D, et al. A consensus on the medical treatment of acromegaly. Nat Rev Endocrinol 2014;10(4):243-8
   PubMed Web of Science ®Google Scholar
• Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 2008;93(8):2957-68
   PubMed Web of Science ®Google Scholar
• Howlett TA, Willis D, Walker G, et al. Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists. Clin Endocrinol (Oxf) 2013;79(5):689-99
   PubMed Web of Science ®Google Scholar
• Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002;87:3013-18
   PubMed Web of Science ®Google Scholar
• Chanson P, Boerlin V, Ajzenberg C, et al. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol (Oxf) 2000;53:577-86
   PubMed Web of Science ®Google Scholar
• Colao A, Auriemma RS, Lombardi G, Pivonello R. Resistance to somatostatin analogs in acromegaly. Endocr Rev 2011;32(2):247-71
   PubMed Web of Science ®Google Scholar
• Colao A, Bronstein MD, Freda P, et al. Pasireotideversusoctreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 2014;99(3):791-9
   PubMed Web of Science ®Google Scholar
• Colao A, Bronstein MD, Brue T, et al. Phase III, multicenter, randomized study (PAOLA) demonstrating that pasireotide LAR has superior efficacy over octreotide LAR and lanreotide ATG in patients with inadequately controlled acromegaly [abstract PP17-2]. ICE/ENDO; 21 – 24 June 2014; Chicago (USA)
   Google Scholar
• Chen WY, Wight DC, Wagner TE, Kopchick JJ. Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mine. Proc Natl Acad Sci USA 1990;87:5061-5
   PubMedGoogle Scholar
• Fug G, Cunningham BC, Fukunaga R, et al. Rational design of potent antagonists to the human growth hormone. Science 1992;256:1677-80
   Google Scholar
• Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000;342(16):1171-7
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Muller AF, Janssen JA, et al. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J Clin Endocrinol Metab 2001;86(2):478-81
   Google Scholar
• Muller AF, Kopchick JJ, Flyvbjerg A, van der Lely AJ. Clinical review 166: growth hormone receptor antagonists. J Clin Endocrinol Metab 2004;89(4):1503-11
   PubMedGoogle Scholar
• Maamra M, Kopchick JJ, Strasburger CJ, Ross RJ. Pegvisomant, a growth hormone-specific antagonist, undergoes cellular internalization. J Clin Endocrinol Metab 2004;89:4532-7
   Google Scholar
• Plockinger U. Medical therapy of acromegaly. Int J Endocrinol 2012;2012:268957
   Google Scholar
• Colao A, Pivonello R, Auriemma RS, et al. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 2006;154(3):467-77
   PubMed Web of Science ®Google Scholar
• Colao A, Arnaldi G, Beck-Peccoz P, et al. Pegvisomant in acromegaly: why, when, how. J Endocrinol Invest 2007;30(8):693-9
   PubMed Web of Science ®Google Scholar
• Jehle S, Reyes CM, Sundeen RE, Freda PU. Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-i levels in patients with acromegaly. J Clin Endocrinol Metab 2005;90(3):1588-93
   PubMed Web of Science ®Google Scholar
• Higham CE, Thomas JDJ, Bidlingmaier M, et al. Successful use of weekly pegvisomant administration in patients with acromegaly. Eur J Endocrinol 2009;161:21-5
   PubMed Web of Science ®Google Scholar
• Jallad RS, Bronstein MD. The place of medical treatment of acromegaly: current status and perspectives. Expert Opin Pharmacother 2013;14(8):1001-15
   PubMed Web of Science ®Google Scholar
• Drake WM, Parkinson C, Akker SA, et al. Successful treatment of resistant acromegaly with a growth hormone receptor antagonist. Eur J Endocrinol 2001;145(4):451-6
   PubMed Web of Science ®Google Scholar
• Parkinson C, Whatmore AJ, Yates AP, et al. The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly. Clin Endocrinol (Oxf) 2003;59(2):168-74
   PubMed Web of Science ®Google Scholar
• Barkan AL, Burman P, Clemmons DR, et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 2005;90(10):5684-91
   PubMed Web of Science ®Google Scholar
• Pivonello R, Galderisi M, Auriemma RS, et al. Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. J Clin Endocrinol Metab 2007;92(2):476-82
   PubMed Web of Science ®Google Scholar
• Schreiber I, Buchfelder M, Droste M, et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 2007;156(1):75-82
   PubMed Web of Science ®Google Scholar
• Buchfelder M, Schlaffer S, Droste M, et al. The German ACRO STUDY: past and present. Eur J Endocrinol 2009;161(Suppl 1):S3-S10
   PubMed Web of Science ®Google Scholar
• Higham CE, Chung TT, Lawrance J, et al. Long-term experience of pegvisomant therapy as a treatment for acromegaly. Clin Endocrinol (Oxf) 2009;71(1):86-91
   PubMed Web of Science ®Google Scholar
• Marazuela M, Lucas T, Alvarez-Escolá C, et al. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy. Eur J Endocrinol 2009;160(4):535-42
   PubMed Web of Science ®Google Scholar
• Trainer PJ, Ezzat S, D’Souza GA, et al. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf) 2009;71(4):549-57
   PubMed Web of Science ®Google Scholar
• Trainer PJ. ACROSTUDY: the first 5 years. Eur J Endocrinol 2009;161(Suppl 1):S19-24
   PubMed Web of Science ®Google Scholar
• Filopanti M, Olgiati L, Mantovani G, et al. Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study. J Clin Endocrinol Metab 2012;97(2):E165-72
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Biller BM, Brue T, et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 2012;97(5):1589-97
   PubMed Web of Science ®Google Scholar
• Auriemma RS, Pivonello R, De Martino MC, et al. Treatment with GH receptor antagonist in acromegaly: effect on cardiac arrhythmias. Eur J Endocrinol 2012;168(1):15-22
   Google Scholar
• Bergamaschi S, Ronchi CL, Giavoli C, et al. Eight-year follow-up of a child with a GH/prolactin-secreting adenoma: efficacy of pegvisomant therapy. Horm Res Paediatr 2010;73(1):74-9
   Google Scholar
• Goldenberg N, Racine MS, Thomas P, et al. Treatment of pituitary gigantism with the growth hormone receptor antagonist pegvisomant. J Clin Endocrinol Metab 2008;93(8):2953-6
   Google Scholar
• Main KM, Sehested A, Feldt-Rasmussen U. Pegvisomant treatment in a 4-year-old girl with neurofibromatosis type 1. Horm Res 2006;65(1):1-5
   Google Scholar
• Rix M, Laurberg P, Hoejberg AS, Brock-Jacobsen B. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl. Eur J Endocrinol 2005;153(2):195-201
   Google Scholar
• Feenstra J, de Herder WW, ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005;365(9471):1644-6
   PubMed Web of Science ®Google Scholar
• Jørgensen JO, Feldt-Rasmussen U, Frystyk J, et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 2005;90(10):5627-31
   PubMed Web of Science ®Google Scholar
• Neggers SJ, van Aken MO, Janssen JA, et al. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab 2007;92(12):4598-601
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Bernabeu I, Cap J, et al. Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur J Endocrinol 2011;164(3):325-33
   PubMed Web of Science ®Google Scholar
• Bianchi A, Valentini F, Iuorio R, et al. Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes. J Exp Clin Cancer Res 2013;32:40
   PubMed Web of Science ®Google Scholar
• Neggers SJ, de Herder WW, Janssen JA, et al. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol 2009;160(4):529-33
   PubMed Web of Science ®Google Scholar
• Neggers SJ, van Aken MO, de Herder WW, et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab 2008;93(10):3853-9
   PubMed Web of Science ®Google Scholar
• Bernabeu I, Alvarez-Escolá C, Paniagua AE, et al. Pegvisomant and cabergoline combination therapy in acromegaly. Pituitary 2013;16(1):101-8
   PubMed Web of Science ®Google Scholar
• Higham CE, Atkinson AB, Aylwin S, et al. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. J Clin Endocrinol Metab 2012;97(4):1187-93
   PubMed Web of Science ®Google Scholar
• Buchfelder M, Weigel D, Droste M, et al. Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. Eur J Endocrinol 2009;161(1):27-35
   PubMed Web of Science ®Google Scholar
• Frohman LA, Bonert V. Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy. Pituitary 2007;10(3):283-9
   Google Scholar
• Bonert VS, Kennedy L, Petersenn S, et al. Lypodystrophy in patients with acromegaly receiving pegvisomant. J Clin Endocrinol Metab 2008;93(9):3515-18
   Web of Science ®Google Scholar
• Hodish I, Barkan A. Long-term effects of pegvisomant in patients with acromegaly. Nat Clin Pract Endocrinol Metab 2008;4(6):324-32
   Google Scholar
• Biering H, Saller B, Bauditz J, et al. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. Eur J Endocrinol 2006;154(2):213-20
   Web of Science ®Google Scholar
• Bernabeu I, Marazuela M, Lucas T, et al. Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert’s syndrome. J Clin Endocrinol Metab 2010;95(5):2147-54
   Web of Science ®Google Scholar
• Jimenez C, Burman P, Abs R, et al. Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. Eur J Endocrinol 2008;159(5):517-23
   Google Scholar
• Buhk JH, Jung S, Psychogios MN, et al. Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. J Clin Endocrinol Metab 2010;95(2):552-8
   PubMed Web of Science ®Google Scholar
• Maffei P, Martini C, Pagano C, et al. Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist pegvisomant. Ann Intern Med 2006;145(4):310-12
   Google Scholar
• Sesmilo G, Resmini E, Bernabeu I, et al. Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study. Clin Endocrinol (Oxf) 2014. [ Epub ahead of print]
   Google Scholar
• Didoni G, Grottol S, Gasco V, et al. Cost-of-illness study in acromegalic patients in Italy. J Endocrinol Invest 2004;27(11):1034-9
   PubMed Web of Science ®Google Scholar
• Ben-Shlomo A, Sheppard MC, Stephens JM, et al. Clinical, quality of life, and economic value of acromegaly disease control. Pituitary 2011;14(3):284-94
   PubMed Web of Science ®Google Scholar
• Moore DJ, Adi Y, Connock MJ, Bayliss S. Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation. BMC Endocr Disord 2009;9:20
   PubMedGoogle Scholar
• Neggers SJ, van der Lely AJ. Combination treatment with somatostatin analogues and pegvisomant in acromegaly. Growth Horm IGF Res 2011;21(3):129-33
   PubMed Web of Science ®Google Scholar
• Giustina A, Chanson P, Kleinberg D, et al. Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol 2014;10(4):243-8
   PubMed Web of Science ®Google Scholar